Search results for "PU-WS13"

showing 1 items of 1 documents

The GRP94 Inhibitor PU-WS13 Decreases M2-like Macrophages in Murine TNBC Tumors: A Pharmaco-Imaging Study with 99mTc-Tilmanocept SPECT

2021

Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancers and is not eligible for hormone and anti-HER2 therapies. Identifying therapeutic targets and associated biomarkers in TNBC is a clinical challenge to improve patients’ outcome and management. High infiltration of CD206+ M2-like macrophages in the tumor microenvironment (TME) indicates poor prognosis and survival in TNBC patients. As we previously showed that membrane expression of GRP94, an endoplasmic reticulum chaperone, was associated with the anti-inflammatory profile of human PBMC-derived M2 macrophages, we hypothesized that intra-tumoral CD206+ M2 macrophages expressing GRP94 may represent innovative…

QH301-705.5GRP94M2-like macrophages03 medical and health sciences0302 clinical medicineBreast cancerIn vivoSpect imagingmedicineBiology (General)Triple-negative breast cancerGRP94; M2-like macrophages; triple-negative breast cancer; PU-WS13; SPECT imaging; biomarker; CD206; Tilmanocept030304 developmental biology0303 health sciencesTumor microenvironmentSPECT imagingbusiness.industryGeneral Medicinemedicine.diseasePU-WS133. Good health030220 oncology & carcinogenesisCancer researchtriple-negative breast cancerBiomarker (medicine)biomarkerbusinessCD8HormoneCells
researchProduct